Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Commit To Buy Clovis Oncology At $65, Earn 16.4% Annualized Using Options
Friday, March 6, 11:32 AM ET, by Market News Video Staff

Investors eyeing a purchase of Clovis Oncology Inc (CLVS) stock, but cautious about paying the ...

Use Options For a Chance To Buy CLVS at a 43% Discount
Tuesday, July 14, 11:43 AM ET, by Market News Video Staff

Looking back to 6 days ago, Clovis Oncology Inc (CLVS) priced a 3,525,641 share secondary ...

First Week of September 18th Options Trading For Clovis Oncology (CLVS)
Tuesday, July 21, 11:20 AM ET, by Market News Video Staff

Investors in Clovis Oncology Inc (CLVS) saw new options begin trading this week, for the ...

Oversold Conditions For Clovis Oncology (CLVS)
Friday, August 14, 12:04 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Clovis Oncology Breaks Below 200-Day Moving Average - Notable for CLVS
Thursday, August 20, 5:07 PM ET, by Market News Video Staff

In trading on Thursday, shares of Clovis Oncology Inc (CLVS) crossed below their 200 day ...

  More articles:  1 2 3 4 5 6 7 next »

Oversold Conditions For Clovis Oncology Inc (CLVS)

By Market News Video Staff, Monday, November 12, 12:55 PM ET
Play Video: Learn About The RSI

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Monday, shares of Clovis Oncology Inc (NASDAQ:CLVS) entered into oversold territory, hitting an RSI reading of 21.6, after changing hands as low as $12.45 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 33.1. A bullish investor could look at CLVS's 21.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of CLVS shares:

Clovis Oncology Inc 1 Year Performance Chart

Looking at the chart above, CLVS's low point in its 52 week range is $11.45 per share, with $27.55 as the 52 week high point that compares with a last trade of $13.93. Find out what 9 other oversold stocks you need to know about

Special Offer: Manage the risks of the markets better with a free 30 day trial to the Strategic Risk Management System.

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Buffett   CLVS   Know   Looking   Management   Oversold   Relative   Special   Start   Strategic   Warren   analysis   below   better   bullish   changing   chart   comparison   entered   entry   falls   fearful   greedy   heavy   into   investor   know   level   look   markets   others   oversold   point   range   raquo   reading   selling   share   shares   sign   stock   technical   territory   that   trading   week   what   when   which   with
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Stock Message Boards Stock Market Definitions

Oversold Conditions For Clovis Oncology Inc (CLVS) | Market News Video | Copyright © 2008 - 2016, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.